journal
MENU ▼
Read by QxMD icon Read
search

Neurodegenerative Disease Management

journal
https://www.readbyqxmd.com/read/30051753/double-blind-randomized-and-controlled-trial-of-epi-743-in-friedreich-s-ataxia
#1
Theresa Zesiewicz, Jason L Salemi, Susan Perlman, Kelly L Sullivan, Jessica D Shaw, Yangxin Huang, Charles Isaacs, Clifton Gooch, David R Lynch, Matthew B Klein
AIM: To evaluate the safety and clinical effects of EPI-743 in Friedreich's ataxia patients. EPI-743 is a compound that targets oxidoreductase enzymes essential for redox control of metabolism. METHODS: We conducted a multicenter trial that evaluated EPI-743 during a 6-month placebo-controlled phase, followed by an 18-month open-label phase. End points included low-contrast visual acuity and the Friedreich's Ataxia Rating Scale. RESULTS/CONCLUSION: EPI-743 was demonstrated to be safe and well tolerated...
July 27, 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/30043671/cardiovascular-function-is-related-to-neuromuscular-performance-in-parkinson-s-disease
#2
Mahmoud A Alomari, Hanan Khalil, Omar F Khabour, Robert Wood
AIM: The current study examined the relationship of handgrip, leg and arm neuromuscular performance with cardiovascular function in patients with Parkinson's disease (PD). MATERIALS & METHODS: Blood pressure, vascular measures and handgrip, shoulder and leg neuromuscular performance were obtained in PD persons and healthy controls. RESULTS: The data reveal that muscular and cardiovascular functions are altered (p < 0.05) in PD. Most importantly, regression indicates that altered central and peripheral cardiovascular function measures demonstrate a moderately strong relationship (p < 0...
July 25, 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/30040034/features-on-cerebral-imaging-suggesting-mitochondrial-disorder
#3
Josef Finsterer
No abstract text is available yet for this article.
July 24, 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/30040030/cannabinoids-for-the-treatment-of-behavioral-and-psychological-symptoms-of-dementia
#4
Rajesh R Tampi, Juan J Young, Deena J Tampi
No abstract text is available yet for this article.
July 24, 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/30040029/5-ht-1a-agonists-and-dyskinesia-in-parkinson-s-disease-a-pharmacological-perspective
#5
Philippe Huot
No abstract text is available yet for this article.
July 24, 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/30040024/psychometric-properties-of-apathy-scales-in-parkinson-s-disease-a-systematic-review
#6
Dana Mohammad, Courtney Ellis, Allison Rau, Myuri Ruthirakuhan, Krista L Lanctôt, Nathan Herrmann
Apathy is among the most prevalent neuropsychiatric symptom experienced in Parkinson's disease (PD) and can be assessed with a variety of scales. To identify which scale is most suitable for apathy assessment in PD, the psychometric properties of each scale and its sensitivity to change were analyzed. The methodological quality of the studies ranged from adequate to excellent. The Lille Apathy Rating Scale demonstrated consistently favorable psychometric properties and was used in two of four clinical trials found...
July 24, 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/30040019/dementia-in-super-aged-japan-challenges-and-solutions
#7
Iracema Leroi, Keiko Kitagawa, Sabina Vatter, Taro Sugihara
Japan, as a 'super-aged' society, is at the forefront of the socioeconomic change resulting from the unprecedented demographic shift of aging societies, and is an exemplar for other countries. Within neurodegenerative disorders, a deeper understanding of the issues faced by aging societies, and their ramifications on the mental well being and cognitive health of older adults, is important. Japan's pioneering approaches in assistive technology and 'gerontotechnology' have the potential to enhance the field of dementia in terms of assessment, diagnosis and care...
July 24, 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29975112/noninvasive-options-for-wearing-off-in-parkinson-s-disease-a-clinical-consensus-from-a-panel-of-uk-parkinson-s-disease-specialists
#8
Robin Fackrell, Camille B Carroll, Donald G Grosset, Biju Mohamed, Prashanth Reddy, Miriam Parry, Kallol Ray Chaudhuri, Tom Foltynie
In the past 4 years, two adjunctive treatment options to levodopa have been licensed for use in the UK in patients with Parkinson's disease (PD) and motor fluctuations: opicapone, a third-generation catechol-O-methyl transferase inhibitor, and safinamide, a monoamine oxidase B inhibitor. This clinical consensus outlines the practical considerations relating to motor fluctuations and managing wearing-off in patients with PD, and provides a clinical insight to adjunctive treatment options, including opicapone and safinamide...
July 5, 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29869572/repository-corticotropin-injection-in-multiple-sclerosis-an-update
#9
Christen F Kutz, Amy L Dix
Relapse management is a crucial component of multiple sclerosis care. Acute relapses are defined as new neurological symptoms or worsening of existing symptoms persisting for >24 h that are not attributable to heat, overexertion, or infection. The most commonly used treatment for multiple sclerosis relapse is a 3-5-day course of corticosteroids, primarily intravenous methylprednisolone with or without oral steroid taper. Repository corticotropin injection is also the US FDA-approved option for managing acute relapse, particularly in the patients with inadequate response, intolerability or allergy to corticosteroid treatment; poor venous access; or limited ability to receive home or clinic infusions...
June 5, 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29943695/reflections-of-the-use-of-locating-technologies-with-persons-with-dementia-proceedings-of-a-key-stakeholder-forum
#10
Noelannah Neubauer, Loretta M Hillier, Cathy Conway, Ron Beleno, Lili Liu
AIM: To describe the proceedings and outcomes of a Locating Technology and Dementia Forum that brought together 109 representatives of researchers, product manufacturers, policy makers, Alzheimer Societies, clinicians, first responders, persons with dementia and care partners. METHODS: Information gathered from this event was used to create strategic direction for advancing the development and use of locating technologies among persons with dementia. RESULTS: Key recommendations from this forum include the need to: fund and conduct research pertaining to usability and effectiveness of technologies; increase awareness about the risk of missing person events; develop a guideline of strategies to manage critical wandering; and engage users in technology development and evaluation...
June 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29943694/myasthenia-gravis-the-unmet-needs-of-a-paradigmatic-autoimmune-disease
#11
Pedro J Modrego
No abstract text is available yet for this article.
June 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29943693/phase-iii-sunbeam-and-radiance-part-b-trials-for-ozanimod-in-relapsing-multiple-sclerosis-demonstrate-superiority-versus-interferon-%C3%AE-1a-avonex-%C3%A2-in-reducing-annualized-relapse-rates-and-mri-brain-lesions
#12
Volker Koscielny
Biography: Volker Koscielny, MD, is the Vice President, Global Medical Affairs, for Inflammation and Immunology at Celgene. Volker trained as a doctor in his native Germany and worked for several pharmaceutical companies prior to joining Celgene in January 2015.
June 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29943692/increases-in-fatigue-do-not-change-spasticity-scores-in-persons-with-multiple-sclerosis
#13
Herbert Karpatkin, Suzanne Babyar, Stefanie DiCarrado, Melissa McDarby, Morris Narovlianski, Beremis Perez, Iman Rimawi
AIM: Fatigue is a common finding in multiple sclerosis (MS) which may result in worsening of gait, function and other MS symptoms, like spasticity. Although the worsening of spasticity with fatigue has been reported by persons with MS, the effect of fatigue on spasticity has not been measured. PURPOSE: The purpose of this study was to compare lower extremity Modified Ashworth Scale (MAS) scores of persons with mild-to-moderate MS symptoms before and after fatigued and unfatigued conditions...
June 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29888987/role-of-epigenetics-in-alzheimer-s-disease-pathogenesis
#14
Andrea Stoccoro, Fabio Coppedè
Advances in molecular biology technologies have allowed uncovering the role of epigenetic regulation in several complex diseases, such as cancer and neurodegenerative disorders. Although the role of epigenetic mechanisms in Alzheimer's disease is still little understood, recent findings clearly show that such mechanisms are dysregulated during disease progression, already in its early stages. However, it is not clear if the observed epigenetic changes represent a cause or a consequence of the disease. Promising results are emerging from studies performed in peripheral blood DNA that could provide early biomarkers of the pathology...
June 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29888648/dopamine-bdnf-and-motor-function-postbilateral-anodal-transcranial-direct-current-stimulation-in-parkinson-s-disease
#15
Hikmat Hadoush, Saleem A Banihani, Hanan Khalil, Yasir Al-Qaisi, Alham Al-Sharman, Muhammed Al-Jarrah
AIM: To examine BDNF, dopamine, and motor function changes after bilateral anodal transcranial direct current stimulation (tDCS) in patients with Parkinson's disease. METHODS: 20 patients undertook ten sessions of bilateral anodal tDCS stimulation applied simultaneously over FC1/FC2, targeting left and right prefrontal and motor areas. Dopamine and BDNF serum levels, and Movement Disorders Society - Unified Parkinson's Disease Rating Scale part three (MDS-UPDRS-III) total score and disability sub-scores were examined pre/post-tDCS stimulation...
June 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29851356/effect-of-tetrahydrocannabinol-cannabidiol-oromucosal-spray-on-activities-of-daily-living-in-multiple-sclerosis-patients-with-resistant-spasticity-a-retrospective-observational-study
#16
Javier Mallada Frechín
AIM: To examine evolution in activities of daily living (ADL) in patients with multiple sclerosis spasticity during long-term use of tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray. METHODS: Functional impairment was assessed retrospectively (prior to start of treatment) and at the present moment using a 16-item ADL survey; results were compared. A control group without add-on THC:CBD oromucosal spray was included to investigate possible recall bias...
June 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29633651/age-disease-duration-influence-on-activities-of-daily-living-and-quality-of-life-after-levodopa-carbidopa-intestinal-gel-in-parkinson-s-disease
#17
Angelo Antonini, Weining Z Robieson, Lars Bergmann, Ashley Yegin, Werner Poewe
AIM: To determine if age and Parkinson's disease duration at therapy initiation influence the efficacy of levodopa-carbidopa intestinal gel (LCIG) on quality of life and activities of daily living. PATIENTS & METHODS: This post hoc analysis assessed subgroups of patients stratified by baseline age, disease duration, hours/day of 'off' time and levodopa equivalent dose. Patients' data were collected from the GLORIA study, a 24-month observational registry evaluating long-term effectiveness of LCIG...
June 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29694267/treatment-and-comorbidities-of-multiple-sclerosis-in-an-employed-population-in-japan-analysis-of-health-claims-data
#18
Mieko Ogino, Aki Shiozawa, Hiroyuki Ota, Shuichi Okamoto, Shinzo Hiroi, Izumi Kawachi
AIM: Use real-world data to investigate the treatment, comorbidities and prevalence of multiple sclerosis (MS) in an employed Japanese population. METHODS: Data from the Japanese Medical Data Center health insurance claims database were analyzed (January 2005-November 2014). Patients with claims associated with an MS diagnosis were identified (n = 494) and comorbidities and prescribed treatments were investigated. MS prevalence within the database was calculated for each calendar year (2011-2013) Results: IFN-β and prednisolone were the most commonly prescribed treatments...
April 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29693485/toward-adaptive-deep-brain-stimulation-in-parkinson-s-disease-a-review
#19
Ameer Mohammed, Richard Bayford, Andreas Demosthenous
Clinical deep brain stimulation (DBS) is now regarded as the therapeutic intervention of choice at the advanced stages of Parkinson's disease. However, some major challenges of DBS are stimulation induced side effects and limited pacemaker battery life. Side effects and shortening of pacemaker battery life are mainly as a result of continuous stimulation and poor stimulation focus. These drawbacks can be mitigated using adaptive DBS (aDBS) schemes. Side effects resulting from continuous stimulation can be reduced through adaptive control using closed-loop feedback, while those due to poor stimulation focus can be mitigated through spatial adaptation...
April 2018: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29683408/palatability-and-oral-cavity-tolerability-of-thc-cbd-oromucosal-spray-and-possible-improvement-measures-in-multiple-sclerosis-patients-with-resistant-spasticity-a-pilot-study
#20
Giacomo Lus, Roberto Cantello, Maura Chiara Danni, Agusto Rini, Paola Sarchielli, Tiziana Tassinari, Elisabetta Signoriello
AIM: Complaints about Δ9 -tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray (Sativex® ; GW Pharma Ltd, Salisbury, UK) in the management of multiple sclerosis spasticity include unpleasant taste and oral mucosal anomalies. This pilot study assessed the use of sugar-free chewing gum and/or a refrigerated bottle of THC:CBD oromucosal spray to mitigate these effects. MATERIALS & METHODS: Patients with multiple sclerosis spasticity (n = 52) at six sites in Italy who were receiving THC:CBD oromucosal spray and had associated oral mucosal effects were randomized into Group A (chewing gum; n = 15); Group B (cold bottle; n = 20); and Group C (cold bottle + chewing gum; n = 17)...
April 2018: Neurodegenerative Disease Management
journal
journal
42631
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"